Published in JAMA on July 10, 1996
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol (1996) 2.03
Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Genitourin Med (1997) 1.94
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother (1999) 1.32
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr (2011) 0.94
The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag (2007) 0.78
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. J Int AIDS Soc (2006) 0.78
Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. Expert Opin Pharmacother (2012) 0.76
Disease management--constructing optimal NRTI-based combinations: past, present, and future. MedGenMed (2006) 0.75
Lamivudine-zidovudine treatment and clinical end points. JAMA (1996) 0.75
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates, and changed sexual behaviour in homosexual men in London. Lancet (1987) 7.71
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurol Sci (1973) 6.62
M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 6.61
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet (2001) 5.34
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 4.98
The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect (2001) 4.95
The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem (2005) 4.94
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology (1998) 4.01
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature (1990) 3.84
Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax (2004) 3.77
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. BMJ (1989) 3.43
Growth, survival, and resistance of the Legionnaires' disease bacterium. Ann Intern Med (1979) 3.36
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
S-nitrosothiols signal the ventilatory response to hypoxia. Nature (2001) 3.26
Open access clinic providing HIV-I antibody results on day of testing: the first twelve months. BMJ (1991) 3.17
Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet (1995) 2.90
Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis (1999) 2.81
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Hepatitis C virus: evidence for sexual transmission. BMJ (1991) 2.50
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
Theophylline prescribing, serum concentrations, and toxicity. Lancet (1983) 2.40
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci (1999) 2.24
Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS (1996) 2.22
The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol (2000) 2.20
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet (1995) 2.17
Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin Exp Immunol (1993) 2.17
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 2.15
A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol (1992) 2.15
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis (2006) 2.09
Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol (1998) 2.08
Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med (1986) 2.06
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS (1992) 2.06
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol (2001) 2.04
Infectious liver diseases in three groups of Copenhagen workers: correlation of hepatitis A infection to sewage exposure. Arch Environ Health (1981) 2.03
[Antimicrobial therapy in exacerbated chronic obstructive pulmonary disease]. Arch Bronconeumol (2002) 2.03
[Cytomegalovirus infection. A review]. Ugeskr Laeger (1993) 2.02
[Therapeutic options for HIV infection should lead to increased utilization of HIV tests]. Ned Tijdschr Geneeskd (1999) 2.01
Epidemiology of cerebral palsy in England and Scotland, 1984-9. Arch Dis Child Fetal Neonatal Ed (1998) 2.01
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. AIDS (1994) 1.93
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. Histochem J (1990) 1.89
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Tenofovir-associated renal and bone toxicity. HIV Med (2009) 1.82
Prevalence of Campylobacter-associated diarrhea among patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 1.80
Increasing frequency of vertebral osteomyelitis following Staphylococcus aureus bacteraemia in Denmark 1980-1990. J Infect (1997) 1.79
HHV-6 in AIDS. Lancet (1994) 1.76
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 1.75
Infrared signature of structures associated with the H+(H2O)n (n = 6 to 27) clusters. Science (2004) 1.71
Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother (2006) 1.70
Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet (1999) 1.69
HIV results in the frame. Results confirmed. Nature (1995) 1.69
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.68
Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol (1991) 1.68
Biochemistry of Oleoresinosis : Monoterpene and Diterpene Biosynthesis in Lodgepole Pine Saplings Infected with Ceratocystis clavigera or Treated with Carbohydrate Elicitors. Plant Physiol (1987) 1.68
Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS (1997) 1.68
A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle. Am J Hum Genet (1997) 1.68
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis (1998) 1.67
Further observations on the pathological responses of rat skeletal muscle to toxins isolated from the venom of the Australian tiger snake, Notechis scutatus scutatus. Clin Exp Pharmacol Physiol (1979) 1.66
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 1.65
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (1996) 1.64
Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect (1997) 1.64
Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis (1995) 1.64
Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin (2003) 1.62
Branhamella (Neisseria) catarrhalis--a lower respiratory tract pathogen? J Clin Microbiol (1981) 1.61
Early maternal and neonatal morbidity associated with operative delivery in second stage of labour: a cohort study. Lancet (2001) 1.61
Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect (2007) 1.61
Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol (2000) 1.61
Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax (2006) 1.60
Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol (1998) 1.57